Struik rejoins Frazier Healthcare

Hendrik Struik has re-joined Frazier Healthcare Partners as an Operating Partner on the Growth Buyout team. Struik is the former Chief Executive Officer of Laboratory Supply Company, a Frazier portfolio company. He rejoined Frazier after McKesson Corp acquired LABSCO in May.

PRESS RELEASE

SEATTLE–(BUSINESS WIRE)–Frazier Healthcare Partners, a leading provider of growth capital to healthcare companies, announced today that Hendrik Struik has re-joined the firm as an Operating Partner on the Growth Buyout team. He will assist the Growth Buyout team with identifying and executing opportunities in the differentiated medical products and supplies space.

“We enthusiastically welcome Hank back to the Frazier Growth Buyout team,” said Ben Magnano, General Partner. “Hank is an experienced, talented executive with a long-term track record both with Frazier and in his prior career. We are thrilled he has made the decision to return to us. Hank is a perfect example of the type of person we look for in the spirit of forming long-term partnerships.”
Mr. Struik is the former Chief Executive Officer of Laboratory Supply Company, a Frazier portfolio company. He rejoined Frazier following the successful sale of LABSCO to McKesson Corporation in May of 2016. Mr. Struik originally joined Frazier Healthcare in July 2012 as an Operating Partner, working with the firm’s Growth Buyout team to identify opportunities in differentiated medical products, supplies and devices and outsourced technology-enabled services.
From 2009 to 2012 he served as the Chief Executive Officer and President of Sarnova, a provider of healthcare products to the emergency medical and acute care services markets. While at Sarnova, Mr. Struik sought out best-in-class technology as product anchors, then leveraged them to pull-through supplies.
Prior to Sarnova, Mr. Struik spent over 20 years with Cardinal Health and predecessor companies including Baxter and Allegiance Healthcare. While at Cardinal he led the strategic acquisition of Viasys. Upon completion of the transaction, he assumed the responsibility for four business units including a clinical trials company, a neuro-diagnostics company, a cardio-pulmonary diagnostics business, and a ventilator business. In the latter capacity he served as the President of Cardinal’s $850M Respiratory and Neurocare unit.
About Frazier Healthcare Partners
Founded in 1991, Frazier Healthcare Partners is a leading provider of growth and venture capital to emerging healthcare service and biopharma companies. With nearly $2.9 billion under management, Frazier has invested in over 170 companies ranging from early-stage venture investments to buyouts of profitable lower-middle market companies. For 25 years, Frazier has established itself among entrepreneurs and seasoned executives as the preferred partner to help create and rapidly grow market leading healthcare companies. Frazier Healthcare Partners has offices in Seattle, Wash., and Menlo Park, Calif., and invests broadly across the United States, Canada and Europe.
For more information about Frazier Healthcare Partners, visit the company’s website at http://www.frazierhealthcare.com.